Pivot-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors

被引：0

作者：

Diab, Adi ^{[1
]}

Tannir, Nizar ^{[1
]}

Cho, Daniel ^{[2
]}

Papadimitrakopoulou, Vali ^{[1
]}

Bernatchez, Chantale ^{[1
]}

Haymaker, Cara ^{[1
]}

Bentebibel, Salah Eddine ^{[1
]}

Curti, Brendan ^{[3
,4
]}

Wong, Michael ^{[1
]}

Tykodi, Scott ^{[5
,6
]}

Puzanoff, Igor ^{[7
]}

Smalberg, Ira ^{[7
]}

Gergel, Ivan ^{[8
]}

Tagliaferri, Mary ^{[8
]}

Zalevsky, Jonathan ^{[8
]}

Hoch, Ute ^{[8
]}

Aung, Sandra ^{[8
]}

Imperiale, Michael ^{[8
]}

Clemens, Wendy ^{[9
]}

Kluger, Harriet ^{[10
]}

Hurwitz, Michael ^{[10
]}

Hwu, Patrick ^{[1
]}

Sznol, Mario ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] NYU Med Oncol Associates, New York, NY USA

[3] Providence Canc Ctr, Portland, OR USA

[4] Earle A Chiles Res Inst, Portland, OR USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] Nektar Therapeut, San Francisco, CA USA

[9] Bristol Myers Squibb, Lawrence Township, NJ USA

[10] Yale Sch Med, New Haven, CT USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O20

引用

页数：1

共 50 条

[31] A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+solid tumors
Schlechter, Benjamin
Dumbrava, Ecaterina
Saibil, Samuel
Gutierez, Martin
Iqbal, Syma
Sohal, Davendra
Apostolopoulou, Maria
Moss, Kara
Adib, Deyaa
Olson, Daniel
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[32] A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+solid tumors
Dumbrava, Ecaterina E.
Olson, Daniel
Saibil, Samuel
Sohal, Davendra P.
Iqbal, Syma
Urgelles, Alejandro
Apostolopoulou, Maria
Mueller, Amy
Moss, Kara
Adib, Deyaa
Schlecter, Ben
CANCER RESEARCH, 2024, 84 (07)
[33] Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study
De La Fuente, Macarena Ines
Ahnert, Jordi Rodon
Yaeger, Rona
Tsai, Frank Yung-Chin
Janku, Filip
Butowski, Nicholas A.
Allen, Carl E.
Ammakkanavar, Natraj Reddy
Taylor, Jennie Webster
Michelson, Glenn
Kline, Irina
Paz, Michael
Tussay-Lindenberg, Alexia
Wong, Kongming
Shepherd, Stacie Peacock
Jiang, Ping
Sherman, Eric Jeffrey
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
Segal, Neil Howard
Girda, Eugenia
Sohal, Davendra
Lakhani, Nehal J.
Olszanski, Anthony J.
Fong, Lawrence
Kinnaman, Michael David
Han, Hyunsil
Skokos, Dimitris
Casey, Kerry A.
Wang, JuAn
Wang, Bei
Hao, Yi
Li, Siyu
Ganguly, Samit
Lowy, Israel
Seebach, Frank A.
Mathias, Melissa Divya
Johnson, Melissa Lynne
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[35] SAFETY, EFFICACY, AND PHARMACOKINETIC RESULTS FROM A PHASE I FIRST-IN-HUMAN STUDY OF ABBV-151 WITH OR WITHOUT ANTI-PD1 MAB (BUDIGALIMAB) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Tolcher, Anthony
Roda-Perez, Desamparados
He, Kai
Moreno, Victor
Gomez-Roca, Carlos
Machiels, Jean-Pascal
Razak, Albiruni
Sahtout, Mohammad
Guan, Xiaowen
Jaryno-Daly, Stacy
Leibman, Rachel
Blaney, Martha
O'Brien, James
Lorusso, Patricia
Powderly, John
Golan, Talia
Miller, Kathy
Bruix, Jordi
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A801 - A801
[36] Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Zhang, P.
Gong, J.
Guo, H.
Han, W.
Cao, B.
Zhang, J.
Niu, Z.
Cheng, Y.
He, C.
Fan, J.
Peng, P.
Sun, C.
Wang, H.
Yu, Y.
Zhu, Y.
Wu, Y.
Li, Q.
Huang, P.
Wu, F.
Shen, L.
ANNALS OF ONCOLOGY, 2023, 34 : S471 - S471
[37] Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891
Powderly, J.
Cassier, P. A.
Cervantes, A.
Gao, B.
Gazzah, A.
Italiano, A.
Lin, C-C.
Luke, J. J.
Moreno, V.
Peltola, K.
Rasco, D.
Spira, A. I.
Tanner, M. M. E.
Tosi, D.
Afar, D.
Englert, S.
Parikh, A.
Reddy, A.
Vosganian, G.
Tolcher, A. W.
ANNALS OF ONCOLOGY, 2018, 29 : 144 - 144
[38] Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
Champiat, Stephane
Cassier, Philippe A.
Kotecki, Nuria
Korakis, Iphigenie
Vinceneux, Armelle
Jungels, Christiane
Blatchford, Jon
Elgadi, Mabrouk M.
Clarke, Nicole
Fromond, Claudia
Poirier, Nicolas
Vasseur, Berangere
Marabelle, Aurelien
Delord, Jean-Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma
Gajewski, Thomas F.
Hamid, Omid
Smith, David C.
Bauer, Todd M.
Wasser, Jeffrey S.
Luke, Jason J.
Balmanoukian, Ani S.
Kaufman, David R.
Zhao, Yufan
Maleski, Janet
Leopold, Lance
Gangadhar, Tara C.
JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
[40] Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study
Naing, Aung
Mamdani, Hirva
Barve, Minal A.
Johnson, Melissa Lynne
Morgensztern, Daniel
Olszanski, Anthony J.
Wolff, Robert A.
Pant, Shubham
Chaney, Marya F.
Adebanjo, Tolani
Fan, Jean
Kim, Richard D.
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →